Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794790 | 0.98 | KDM1A (0.37) | KDM4EMAPTALDH1A1KDM1ATRPV3 | |
| SCHEMBL618002 | 0.95 | TRPV3 (0.38) | MAPTKDM1ATRPV3HTR2CHTT | |
| SCHEMBL3794807 | 0.95 | TRPV3 (0.38) | MAPTKDM1ATRPV3HTR2CHTT | |
| SCHEMBL3804677 | 0.95 | TRPV3 (0.38) | MAPTKDM1ATRPV3HTR2CHTT | |
| SCHEMBL617794 | 0.84 | HTR2C (0.39) | KDM1ATRPV3HTR2CSMN1; SMN2CNR1 | |
| Hydrochloric Acid SCHEMBL6559908 | 0.81 | TRPV1 (0.39) | KDM1AKCNH2 | |
| SCHEMBL13499161 | 0.81 | KDM1A (0.36) | KDM4EKDM1AHTTATMLMNA | |
| SCHEMBL4350339 | 0.81 | KDM4E (0.48) | KDM4EMAPTALDH1A1HTR2CHTT | |
| Hydrochloric Acid SCHEMBL6558690 | 0.79 | TRPV1 (0.40) | KDM1AHTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL11246000 | 0.79 | HTR2B (0.40) | KDM4EMAPTKDM1AHTR2CHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598220-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-7622493-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | OPRL1, AVPR1A, TRPV1 | KDM4E 3574/4885MAPT 3866/4885ALDH1A1 579/4885 |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | KDM4E 3601/4885MAPT 2061/4885ALDH1A1 3317/4885 |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | OPRL1, AVPR1A, AVPR1B | KDM4E 3498/4885MAPT 3827/4885ALDH1A1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.